PDL BioPharma drops on lower 4Q revenue forecast
PDL BioPharma (NASDAQ:PDLI) has dropped by more than 2.6 percent today after the company announced that it expects fourth quarter profits to drop by about 5 percent due to lower royalty payments for...
View ArticleDyax (NASDAQ:DYAX) Stops Clinical Trial of Angioedema Drug Kalbitor – DYAX,...
Dyax Corp (NASDAQ:DYAX) reported on Thursday that the company was discontinuing a clinical experiment of its angioedema medicine Kalbitor as the drug was not working better than a placebo. Kalbitor is...
View ArticleHealthcare Sector Marks Solo Flight to Green Land; Geron (GERN) Ends Brain...
Healthcare sector reacted positively on Monday’s trading session and only sector in the whole market that finished higher. If we look at the key movers of the sector so Pharmacyclics, Inc (NASDAQ:PCYC)...
View ArticleAmarin Corp. (NASDAQ:AMRN)Risks with Vascepa Launch Plunges Stock – AMRN,...
Shares of Amarin Corp. (NASDAQ:AMRN)plunged 17% to $9.87 per share in early trading hours on Friday following the drug manufacturer took out a credit line of $100 million as it sets up for the release...
View Article
More Pages to Explore .....